BioPharmSignal logoBioPharmSignal

Biotech News

Abeona Therapeutics® Announces New Qualified Treatment Center for ZEVASKYN® in Texas

Abeona Therapeutics (ABEO)Abeona TherapeuticsCompany update

ABEO (ABEO) appears in the live feed after a catalyst-style update. The headline is surfaced in real time so readers can move from signal to source without leaving the product flow.

The source domain is abeo.com. BioPharmSignal keeps the ticker, timestamp, and source together for faster review before the wider market catches up.

The original release is available below in a new tab so readers can continue into the full source when needed.

Related news

ABEOAbeona Therapeutics2026-07-21 11:30 EST

Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®

ABEOAbeona Therapeutics2026-08-04 11:30 EST

CMS Grants New Technology Add-On Payment (NTAP) Status for ZEVASKYN®

MNPRMonopar2026-06-30 12:00 EST

Monopar Therapeutics Receives FDA Rare Pediatric Disease Designation for ALXN1840 for the Treatment of Wilson Disease

CAPRCapricor Therapeutics2026-06-26 14:02 EST

Capricor Therapeutics Announces FDA Advisory Committee Meeting to Review BLA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy

PTCTPTC Therapeutics, Inc.2026-08-24 12:00 EST

PTC Therapeutics Announces New Sephience™ (sepiapterin) Data Reinforcing Broad Patient Benefits Including Sustained Metabolic Control and Diet Liberalization as well as Consistent Favorable Safety Profile

SGMOSangamo Therapeutics, Inc.2026-08-12 20:01 EST

Sangamo Therapeutics Selects Successful Bidders Following Competitive Asset Auction for $163.55 Million in Cash Consideration at Closing and Up to $100 Million in Potential Milestones

NTLAIntellia2026-08-06 11:00 EST

Intellia Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates

SRPTSarepta Therapeutics2026-08-05 20:05 EST

Sarepta Therapeutics Announces Second Quarter 2026 Financial Results and Recent Corporate Developments

CAPRCapricor Therapeutics2026-07-30 13:30 EST

Capricor Therapeutics Provides Update on FDA Advisory Committee Meeting for Deramiocel

PHVSPharvaris2026-07-06 10:50 EST

Pharvaris Announces FDA Acceptance of New Drug Application for Deucrictibant IR for On-Demand Treatment of Hereditary Angioedema Attacks

View all latest news

Abeona Therapeutics

Cell and Gene Therapy Company Abeona Therapeutics develops and commercializes genetic medicines for serious diseases. ZEVASKYN ZEVASKYN is an autologous, gene-corrected epidermal sheet therapy for wounds in recessive dystrophic epidermolysis bullosa and provides Abeona with a commercial cell-therapy platform. ABO-701 ABO-701 is an...

Recent company news

ABEOAbeona Therapeutics2026-08-13 11:30 EST

Abeona Therapeutics® Reports Second Quarter 2026 Results and Provides Business Update

ABEOAbeona Therapeutics2026-08-06 11:30 EST

Abeona Therapeutics® to Host Second Quarter 2026 Financial Results Conference Call on August 13, 2026

ABEOAbeona Therapeutics2026-08-04 11:30 EST

CMS Grants New Technology Add-On Payment (NTAP) Status for ZEVASKYN®

ABEOAbeona Therapeutics2026-08-03 11:30 EST

Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

ABEOAbeona Therapeutics2026-07-21 11:30 EST

Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®

Stock data

Close
6.09 USD
Market cap
324.3M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States